US-based degenerative diseases treatment developer Cortexyme has raised $76m in a series B round from investors including Verily Life Sciences, the life sciences subsidiary of diversified conglomerate Alphabet.
Pharmaceutical firms Pfizer and Takeda, through its Takeda Ventures unit, also participated in the round, as did Sequoia Capital, Vulcan Capital, Epiq Capital Group, RSL Investments, Huizenga Capital, Lamond Family, Breakout Ventures and Dolby Family Ventures.
Cortexyme is working on treatments for Alzheimer’s disease and other degenerative disorders. Its lead drug candidate for Alzheimer’s disease, Cor388, is set to enter a phase 2 trial next year after successfully completing initial clinical studies.
Pfizer, Takeda Ventures and Dolby Family Ventures previously backed a $15m series A round in 2016.
The company previously raised $1m in a 2014 seed round backed by Dolby Family Ventures and Breakout Labs, which supplied $350,000 in grant funding.